Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.90, marking a -4.88% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.51% for ...

Recursion Pharmaceuticals Inc. stock reached a 52-week low, hitting $3.78, underscoring a challenging year for the company. Over the past 12 months, the stock has experienced a significant decline, ...

All the Latest Game Footage and Images from Soul Recursion Soul Recursion is a story focused hack and slash challenging you to explore and uncover the mysteries hidden amongst utopian ruins. Games ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached its second release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Rahul Nambiampurath has been writing and reporting about cryptocurrency since 2017. As a fan of decentralized tech, he was fascinated by the Bitcoin whitepaper. Erika Rasure is globally-recognized as ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...